Transcriptomic analysis of skin fibroblasts in scleroderma
Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
Centre Hospitalier Universitaire Dijon · NCT07256418
This project will analyze gene activity in skin fibroblasts from people with systemic scleroderma and from surgical controls to see if fibroblasts contribute to the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon (other) |
| Locations | 1 site (Dijon) |
| Trial ID | NCT07256418 on ClinicalTrials.gov |
What this trial studies
This observational study collects skin samples from adults with systemic scleroderma and from control participants undergoing elective plastic or reconstructive surgery. Researchers will isolate cutaneous fibroblasts and perform transcriptomic analyses to compare gene-expression patterns. The team is particularly interested in signatures of fibroblast senescence, immune activation, and pathways linked to fibrosis. Findings aim to clarify fibroblasts' role in disease mechanisms and to highlight candidate biomarkers or targets for future therapies.
Who should consider this trial
Good fit: Adults with systemic scleroderma who can give written informed consent and have social security coverage are eligible, and control participants are adults undergoing elective plastic or reconstructive surgery without chronic inflammatory or autoimmune skin disease.
Not a fit: People who are minors, unable to consent, under legal protection measures, or without social security coverage are excluded and would not be eligible to participate or benefit from this protocol.
Why it matters
Potential benefit: If successful, the work could identify molecular signatures that help guide development of targeted treatments or biomarkers for disease activity.
How similar studies have performed: Previous transcriptomic studies of skin and fibroblasts in scleroderma have identified fibrosis-related gene signatures and pathways, though translating those findings into approved therapies has been limited so far.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: FOR PATIENTS WITH SCLERODERMA : * Person who has given written consent * Person with systemic scleroderma FOR CONTROL PARTICIPANTS : * Person who has given written consent * Person undergoing plastic, cosmetic and reconstructive surgery Exclusion Criteria: FOR PATIENTS WITH SCLERODERMA : * Person not affiliated to or not benefiting from a social security scheme * Person subject to a legal protection measure (curatorship, guardianship) * Person subject to a legal protection measure * An adult who is incapable or unable to give consent * Minors FOR CONTROLLED PARTICIPANTS : * Person suffering from a chronic disease or under chronic treatment for autoimmune, inflammatory or dermatological diseases * Person not affiliated to or not benefiting from a social security scheme * Person under legal protection (curatorship, guardianship) * Person subject to a legal protection measure * An adult who is incapable or unable to give consent * Minors
Where this trial is running
Dijon
- CHU Dijon Bourgogne — Dijon, France (RECRUITING)
Study contacts
- Study coordinator: Bernard BONNOTTE
- Email: Bernard.bonnotte@chu-dijon.fr
- Phone: 03.80.29.34.32
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Scleroderma